急性淋巴细胞白血病患儿甲氨蝶呤转运蛋白及代谢酶基因多态性的研究进展  

Methotrexate-related transporters and metabolizing enzyme gene polymorphism in children with acute lymphoblastic leukemia

作　　者：杨立莹 李永乐 于冬旭 杨东光[1] YANG Li-ying;LI Yong-le;YU Dong-xu;YANG Dong-guang(Department of Hematology,the First Affiliated Hospital of Harbin Medical University,Harbin,Heilongjiang 150000,China;Department of Infectious Disease,the Second Hospital of Tianjin Medical University,Tianjin 300000,China)

机构地区：[1]哈尔滨医科大学附属第一医院血液内科,黑龙江哈尔滨150000 [2]天津医科大学第二医院感染科,天津300000

出　　处：《中华实用诊断与治疗杂志》2021年第3期317-320,共4页Journal of Chinese Practical Diagnosis and Therapy

基　　金：国家自然科学基金(81500117)。

摘　　要：大剂量甲氨蝶呤治疗儿童急性淋巴细胞白血病的疗效及不良反应具有明显的个体差异。大剂量甲氨蝶呤治疗反应的多样性与甲氨蝶呤相关转运蛋白如溶脂载体转运蛋白、ABC转运蛋白以及甲氨蝶呤代谢相关酶如亚甲基四氢叶酸还原酶、二氢叶酸还原酶、胸腺嘧啶核苷酸合成酶、氨基咪唑胺甲酰转移酶等密切相关。本文就甲氨蝶呤代谢途径,甲氨蝶呤转运蛋白及代谢酶基因多态性对其疗效、不良反应的影响作一综述。The efficacy and toxicity of high-dose methotrexate(MTX)in the treatment of children with acute lymphoblastic leukemia(AML)show significant individual differences.Recent studies have found that the diversity of high-dose MTX treatment response is closely correlated with MTX-related transporters as solute carrier transporter and ABC transporter,as well as MTX metabolizing-related enzymes as methylenetetrahydrofolat reductase,dihydrofolate reductase,thymidylate synthase,and aminoimidazole carboxamide tibonucleotide transformylase.This paper reviews the research progress of the metabolizing pathway of MTX,as well as the influences of MTX-related transporters and metabolizing enzyme gene polymorphism on the efficacy and toxicity.

关 键 词：急性淋巴细胞白血病 甲氨蝶呤 转运蛋白 代谢酶 基因多态性 

分 类 号：R733.71[医药卫生—肿瘤]